Article Information
PubMed
Print ISSN
Online ISSN
History
- Received August 18, 2008
- Accepted November 20, 2008
- Published online January 21, 2009.
Article Versions
- Earlier version (November 24, 2008 - 06:51).
- You are viewing the most recent version of this article.
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Atsushi Ose,
- Mototsugu Ito,
- Hiroyuki Kusuhara,
- Kenzo Yamatsugu,
- Motomu Kanai,
- Masakatsu Shibasaki,
- Masakiyo Hosokawa,
- John D. Schuetz and
- Yuichi Sugiyama
- Graduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, Japan (A.O., M.I., H.K., K.Y., M.K., M.S., Y.S.); Chiba Institute of Science, Choshi-city, Chiba, Japan (M.H.); and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee (J.D.S.)
- Address correspondence to:
Dr. Yuichi Sugiyama, Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp
Statistics from Altmetric.com
Article usage
In this issue
Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4)
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement